PET Response-guided treatment of hodgkins lymphoma: A review of the evidence and active clinical trials

Advances in Hematology

Volumn 2011, Issue , 2011, Pages

  Gajra, Ajeet ^a   Aridgides, Paul ^a   Bogart, Jeffrey ^a   Shapiro, Anna ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PREDNISONE; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; HODGKIN DISEASE; HUMAN; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 79952209765     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2011/309237     Document Type: Review

References (22)

1. Brenner H., Gondos A., Pulte D., Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients Blood 2008 111 6 2977 2983
2. Klimm B., Engert A., Combined modality treatment of Hodgkins lymphoma Cancer Journal 2009 15 2 143 149
3. Engert A., Diehl V., Franklin J., Lohri A., Drken B., Ludwig W. D., Koch P., Hnel M., Pfreundschuh M., Wilhelm M., Trmper L., Aulitzky W. E., Bentz M., Rummel M., Sezer O., Mller-Hermelink H. K., Hasenclever D., Lffler M., Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkins lymphoma: 10 years of follow-up of the GHSG HD9 study Journal of Clinical Oncology 2009 27 27 4548 4554
4. Fabian C. J., Mansfield C. M., Dahlberg S., Jones S. E., Miller T. P., Van Slyck E., Grozea P. N., Morrison F. S., Coltman C. A., Fisher R. I., Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease: a Southwest Oncolog (Pubitemid 24179152)
5. Aleman B. M. P., Raemaekers J. M. M., Tirelli U., Bortolus R., Vant Veer M. B., Lybeert M. L. M., Keuning J. J., Carde P., Girinsky T., Van der Maazen R. W. M., Tomi R., Vovk M., Van Hoof A., Demeestere G., Lugtenburg P. J., Thomas J., Schroyens W., De Boeck K., Baars J. W., Kluin-Nelemans J. C., Carrie C., Aoudjhane M., Bron D., Eghbali H., Smit W. G. J. M., Meerwaldt J. H., Hagenbeek A., Pinna A., Henry-Amar M., Involved-field radiotherapy for advanced Hodgkins lymphoma The New England Journal of Medicine 2003 348 24 2396 2406 (Pubitemid 36682818)
6. Horning S. J., Hoppe R. T., Breslin S., Bartlett N. L., William Brown B., Rosenberg S. A., Stanford V and radiotherapy for locally extensive and advanced Hodgkins disease: mature results of a prospective clinical trial Journal of Clinical Oncology 2002 20 3 630 637 (Pubitemid 34111368)
7. Allen-Auerbach M., Weber W. A., Measuring response with FDG-PET: methodological aspects Oncologist 2009 14 4 369 377
8. Hoekstra O. S., Ossenkoppele G. J., Golding R., Van Lingen A., Visser G. W. M., Teule G. J. J., Huijgens P. C., Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy Journal of Nuclear Medicine 1993 34 10 1706 1710 (Pubitemid 23295382)
9. Kostakoglu L., Coleman M., Leonard J. P., Kuji I., Zoe H., Goldsmith S. J., Pet predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkins disease Journal of Nuclear Medicine 2002 43 8 1018 1027 (Pubitemid 34847924)
10. Torizuka T., Nakamura F., Kanno T., Futatsubashi M., Yoshikawa E., Okada H., Kobayashi M., Ouchi Y., Early therapy monitoring with FDG-PET in aggressive non-Hodgkins lymphoma and Hodgkins lymphoma European Journal of Nuclear Medicine and Molecular Imaging 2004 31 1 22 28 (Pubitemid 38133537)
11. Hutchings M., Mikhaeel N. G., Fields P. A., Nunan T., Timothy A. R., Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma Annals of Oncology 2005 16 7 1160 1168 (Pubitemid 41418320)
12. Hutchings M., Loft A., Hansen M., Pedersen L. M., Buhl T., Jurlander J., Buus S., Keiding S., DAmore F., Boesen A. M., Berthelsen A. K., Specht L., FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma Blood 2006 107 1 52 59 (Pubitemid 43053523)
13. Gallamini A., Rigacci L., Merli F., Nassi L., Bosi A., Capodanno I., Luminari S., Vitolo U., Sancetta R., Iannitto E., Trentin L., Stelitano C., Tavera S., Biggi A., Castagnoli A., Versari A., Gregianin M., Pelosi E., Torchio P., Levis A., The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkins disease Haematologica 2006 91 4 475 481
14. Gallamini A., Hutchings M., Rigacci L., Specht L., Merli F., Hansen M., Patti C., Loft A., Di Raimondo F., DAmore F., Biggi A., Vitolo U., Stelitano C., Sancetta R., Trentin L., Luminari S., Iannitto E., Viviani S., Pierri I., Levis A., Early interim 2-[ F18 ]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkins lymphoma: a report from a joint Italian-Danish study Journal of Clinical Oncology 2007 25 24 3746 3752 (Pubitemid 47372616)
15. Terasawa T., Lau J., Bardet S., Couturier O., Hotta T., Hutchings M., Nihashi T., Nagai H., Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkins lymphoma and diffuse large B-cell lymphoma: a systematic review Journal of Clinical Oncology 2009 27 11 1906 1914
16. Dann E. J., Bar-Shalom R., Tamir A., Haim N., Ben-Shachar M., Avivi I., Zuckerman T., Kirschbaum M., Goor O., Libster D., Rowe J. M., Epelbaum R., Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome Blood 2007 109 3 905 909 (Pubitemid 46220633)
17. Avigdor A., Bulvik S., Levi I., Dann E. J., Shemtov N., Perez-Avraham G., Shimoni A., Nagler A., Ben-Bassat I., Polliack A., Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkins lymphoma Annals of Oncology 2010 21 1 126 132
18. Advani R., Maeda L., Lavori P., Quon A., Hoppe R., Breslin S., Rosenberg S. A., Horning S. J., Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkins disease Journal of Clinical Oncology 2007 25 25 3902 3907 (Pubitemid 47477267)
19. Sher D. J., Mauch P. M., Van Den Abbeele A., LaCasce A. S., Czerminski J., Ng A. K., Prognostic significance of mid- and post-ABVD PET imaging in Hodgkins lymphoma: the importance of involved-field radiotherapy Annals of Oncology 2009 20 11 1848 1853
20. Kobe C., Dietlein M., Franklin J., Markova J., Lohri A., Amthauer H., Klutmann S., Knapp W. H., Zijlstra J. M., Bockisch A., Weckesser M., Lorenz R., Schreckenberger M., Bares R., Eich H. T., Mueller R. P., Fuchs M., Borchmann P., Schicha H., Diehl V., Engert A., Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma Blood 2008 112 10 3989 3994
21. Picardi M., De Renzo A., Pane F., Nicolai E., Pacelli R., Salvatore M., Rotoli B., Randomized comparison of consolidation radiation versus observation in bulky Hodgkins lymphoma with post-chemotherapy negative positron emission tomography scans Leukemia and Lymphoma 2007 48 9 1721 1727 (Pubitemid 47386707)
22. Andre M. P., Reman O., Federico M., First report on the H10 EORTC/GELA/IIL randomized intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supra-diaphragmatic stage I/II Hodgkins lymphoma, for the Groupe dEtude Des Lymphomes De lAdulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano Linfomi (IIL) Proceedings of the 51st American Society Hematology Annual Meeting and Exposition December 2009 New Orleans, La, USA. abstract no. 9